Insight

Sep 2, 2024, 08:40

Durable Responses to Atezolizumab Plus Bevacizumab in HCC

Saadvik Raghuramy shared a post on X about a recent paper by Ying-Chun Shen et al. published in JCO.

“Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab”

Authors: Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, Masatoshi Kudo, Ann-Lii Cheng et al.

“HCC Patients achieving a durable response with ATEZO/BEV i.e. a PR or SD tend to have much more favourable outcome.

mOS not estimatable for patients with durable PR
mOS 23.7 months for durable SD
pCR more frequent with PR (57%).”

Durable Responses to Atezolizumab Plus Bevacizumab in HCC

Source: Saadvik Raghuramy/X

Saadvik Raghuramy is the Head of the Department of Medical Oncology at Arete Hospitals. Dr. Saadvik specializes in treating a wide range of cancers, including breast, stomach, colorectal, liver, esophageal, prostate, kidney, bladder, oral, brain tumors, and lung cancers.

His clinical expertise includes immunotherapy, monoclonal antibody therapy, chemotherapy, cancer screening, palliative care, targeted therapy, clinical trials, cancer genetic counseling, and hormone therapy.

Alan Nicholas Ann-Lii Cheng Arete Hospitals Atezolizumab+Bevacizumab cancer HCC hepatocellular carcinoma JCO Masatoshi Kudo OncoDaily Oncology Saadvik Raghuramy Tsung-Hao Liu Ying-Chun Shen

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results